Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
PARPi routine practice effectiveness between groups mirrors prospective trials. Within the BRCAalt group, BRCAloss had the best outcomes. Unless the ctDNA tumor fraction is very high, somatic tissue testing (archival or metastatic) should be prioritized to identify patients who may benefit most from PARPi. When tissue testing is not clinically feasible, sufficient ctDNA tumor fraction levels for detection are enriched at clinical timepoints associated with tumor progression.
Authors
- Ryon P. Graf (ORCID: https://orcid.org/0000-0002-8065-4148)
- Hanna Tukachinsky (ORCID: https://orcid.org/0000-0002-0777-7555)
- Todd Matthew Morgan (ORCID: https://orcid.org/0000-0002-1140-0603)
- Daniel Triner
- Russell W. Madison (ORCID: https://orcid.org/0000-0002-7838-2526)
- Gerald Li (ORCID: https://orcid.org/0000-0002-5617-6262)
- Heather H. Cheng (ORCID: https://orcid.org/0000-0002-1365-0702)
- Amado J. Zurita (ORCID: https://orcid.org/0000-0002-3805-7307)
- Ole Gjoerup (ORCID: https://orcid.org/0000-0001-9127-8769)
- Colin C. Pritchard (ORCID: https://orcid.org/0000-0002-2461-1557)
- Júlia C.F. Quintanilha (ORCID: https://orcid.org/0000-0001-6908-4474)
- J. Mateo
- M. Cieslik
- Jeffrey S. Ross (ORCID: https://orcid.org/0000-0001-8494-2596)
- Zachery R. Reichert (ORCID: https://orcid.org/0000-0003-0356-8796)
- Tian Zhang (ORCID: https://orcid.org/0000-0001-8914-3531)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
- Qianqian Qin (ORCID: https://orcid.org/0009-0005-5854-2691)
Institutions
- Hebron University (PS)
- The University of Texas MD Anderson Cancer Center (US)
- University of Washington (US)
- SUNY Upstate Medical University (US)
- University of Michigan (US)
- Huntsman Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Southwestern Medical Center (US)
- Vall d'Hebron Institut de Recerca (ES)
- Michigan Medicine (US)
- Vall d'Hebron Hospital Universitari (ES)
- Southwestern Medical Center (US)
- Foundation Medicine (United States)
- Seattle University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103684
- Citations
- 7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Flatiron Health
- Foundation Medicine